Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced an exclusive five-year global supply agreement for NO and NO2 (Nitrogen Dioxide) calibration gas with MESA Specialty Gases & Equipment.
Key Highlights
-
Five year term begins on the earlier of FDA approval for the LungFit™ PH system or December 31, 2020
-
Beyond Air will be responsible for the initial and future costs for adjustments to MESA facilities to meet capacity requirements (estimated to be less than $100,000)
-
Beyond Air has the option to have MESA design and operate a calibration gas manufacturing facility dedicated to Beyond Air
-
Deal is exclusive on a global basis to both companies
Grounding Healthcare Spaces in Hospitality Principles
UC Davis Health Selects Rudolph and Sletten for Central Utility Plant Expansion
Cape Cod Healthcare Opens Upper 2 Floors of Edwin Barbey Patient Care Pavilion
Building Sustainable Healthcare for an Aging Population
Froedtert ThedaCare Announces Opening of ThedaCare Medical Center-Oshkosh